The PD-1 inhibitor pembrolizumab shows antitumor activity in patients with previously treated metastatic castration-resistant prostate cancer, indicate results from the KEYNOTE-028 and KEYNOTE-199 trials.
The content compiled here represents some of the most-accessed original research from recently published Journal of Clinical Oncology articles across a range of topics including prostate and bladder cancer.
Breast cancer-related lymphedema is a debilitating complication of breast cancer surgery. Babak Mehrara (Memorial Sloan Kettering Cancer Center, NY, USA) outlines the current state of lymphedema management and poses some questions for the future.
Melanoma patients with brain metastases can expect to live longer following the incorporation of checkpoint inhibitors and BRAF-targeted therapies into standard care than their counterparts treated prior to the approval of these agents, suggests an analysis of the US National Cancer Database.
Source:
Cancer Immunol Res 2018; doi:10.1158/2326-6066.CIR-18-0067
Targeted delivery of doxorubicin using a thermosensitive liposomal preparation triggered by focused ultrasound appears to be a viable option for the treatment of liver tumors, according to the proof-of-concept TARDOX study.
Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.
The PD-1 inhibitor pembrolizumab shows antitumor activity in patients with previously treated metastatic castration-resistant prostate cancer, indicate results from the KEYNOTE-028 and KEYNOTE-199 trials.
Source:
Ann Oncol 2018; doi:10.1093/annonc/mdy232, ASCO Annual Meeting 2018; Chicago, Illinois, USA
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
